The Food and Drug Administration has approved a new drug applicationfor Gastromark, a gastrointestinal MRI contrast agent developedby Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagneticoral contrast agent that has been licensed to
The Food and Drug Administration has approved a new drug application
for Gastromark, a gastrointestinal MRI contrast agent developed
by Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagnetic
oral contrast agent that has been licensed to Mallinckrodt Medical
of St. Louis. The agent is marketed in Western Europe by Guerbet
under the trade name Lumirem. Gastromark will be priced at about
$25 per 300 mL, according to Jerome Goldstein, president and CEO
of Advanced Magnetics. Either 600 or 900 mL will likely be administered,
bringing the total cost to between $50 and $75 per patient.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.